1. Home
  2. SNTG vs ARTL Comparison

SNTG vs ARTL Comparison

Compare SNTG & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sentage Holdings Inc.

SNTG

Sentage Holdings Inc.

N/A

Current Price

$1.97

Market Cap

5.4M

Sector

Finance

ML Signal

N/A

Logo Artelo Biosciences Inc.

ARTL

Artelo Biosciences Inc.

HOLD

Current Price

$1.34

Market Cap

4.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SNTG
ARTL
Founded
2009
2011
Country
China
United States
Employees
N/A
7
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.4M
4.3M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
SNTG
ARTL
Price
$1.97
$1.34
Analyst Decision
Hold
Analyst Count
0
2
Target Price
N/A
N/A
AVG Volume (30 Days)
11.8K
178.5K
Earning Date
05-13-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.60
$0.94
52 Week High
$12.70
$28.60

Technical Indicators

Market Signals
Indicator
SNTG
ARTL
Relative Strength Index (RSI) 49.12 25.82
Support Level $1.83 $1.08
Resistance Level $2.10 $1.96
Average True Range (ATR) 0.18 0.24
MACD -0.01 -0.09
Stochastic Oscillator 29.31 3.47

Price Performance

Historical Comparison
SNTG
ARTL

About SNTG Sentage Holdings Inc.

Sentage Holdings Inc is a financial service provider that offers a comprehensive range of financial services across consumer loan repayment and collection management, loan recommendation, and prepaid payment network services in China.

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

Share on Social Networks: